A Novel Inhibitor INF 39 Promotes Osteogenesis via Blocking the NLRP3/IL-1β Axis

Figure 4

INF 39 does not have a remarkable effect on osteoclastogenesis. (a) Cell viability of INF 39-treated BMMs tested by CCK-8 assays at 48 and 96 hours. (b) TRAP staining of BMMs treated with various concentrations of INF 39, M-CSF (25 ng/mL), and RANKL (50 ng/mL) for 6 days. (c) Quantification of TRAP-positive multinuclear cells, osteoclast number, area of osteoclasts, and osteoclast size. (d, e) Expression of the osteoclast-specific genes c-Fos and CTSK in BMMs treated with various concentrations of INF 39 (). CTSK: cathepsin K. (f) The gray level of NFATc1 and c-Fos was quantified and normalized to GAPDH using ImageJ ().

(a)

(b)

(c)

(d)

(e)

(f)